Literature DB >> 16978860

The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes.

Magdalena Kowalewska1, Magdalena Chechlińska, Sergiusz Markowicz, Paulina Kober, Radosława Nowak.   

Abstract

Marker genes, commonly used to detect circulating tumour cells in RT-PCR-based tests: squamous-cell carcinoma antigen, epidermal growth factor receptor, mammaglobin, small breast epithelial mucin, but not carbonic anhydrase 9, were shown to be expressed in normal, mitogen-stimulated peripheral blood mononuclear cells (PBMNC). Thus, considering the inflammatory reactions often accompanying cancer development, to reduce false-positive results of the metastatic tumour cell tests, molecular markers should be validated not against normal peripheral blood, but against activated lymphoid cells, such as in vitro mitogen-stimulated PBMNC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16978860     DOI: 10.1016/j.ejca.2006.05.036

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

1.  Systemic inflammation as a confounding factor in cancer biomarker discovery and validation.

Authors:  Magdalena Chechlinska; Magdalena Kowalewska; Radoslawa Nowak
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

2.  Sensitive and easy screening for circulating tumor cells by flow cytometry.

Authors:  Alexia Lopresti; Fabrice Malergue; François Bertucci; Maria Lucia Liberatoscioli; Severine Garnier; Quentin DaCosta; Pascal Finetti; Marine Gilabert; Jean Luc Raoul; Daniel Birnbaum; Claire Acquaviva; Emilie Mamessier
Journal:  JCI Insight       Date:  2019-06-13

Review 3.  Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes.

Authors:  Lori M Millner; Mark W Linder; Roland Valdes
Journal:  Ann Clin Lab Sci       Date:  2013       Impact factor: 1.256

4.  Diagnostic significance of alternative splice variants of REST and DOPEY1 in the peripheral blood of patients with breast cancer.

Authors:  Ave Kris Lend; Anna Kazantseva; Anri Kivil; Vahur Valvere; Kaia Palm
Journal:  Tumour Biol       Date:  2014-11-26

5.  Squamous cell carcinoma antigen 1 and 2 expression in cultured normal peripheral blood mononuclear cells and in vulvar squamous cell carcinoma.

Authors:  Magdalena Chechlinska; Magdalena Kowalewska; Edyta Brzoska-Wojtowicz; Jakub Radziszewski; Konrad Ptaszynski; Janusz Rys; Janina Kaminska; Radoslawa Nowak
Journal:  Tumour Biol       Date:  2010-07-01

6.  Filter characteristics influencing circulating tumor cell enrichment from whole blood.

Authors:  Frank A W Coumans; Guus van Dalum; Markus Beck; Leon W M M Terstappen
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

7.  Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope.

Authors:  T G Ntouroupi; S Q Ashraf; S B McGregor; B W Turney; A Seppo; Y Kim; X Wang; M W Kilpatrick; P Tsipouras; T Tafas; W F Bodmer
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640

8.  Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients.

Authors:  Galatea Kallergi; Sofia Agelaki; Antonia Kalykaki; Christos Stournaras; Dimitris Mavroudis; Vassilis Georgoulias
Journal:  Breast Cancer Res       Date:  2008-09-29       Impact factor: 6.466

9.  Carcinoembryonic antigen and cytokeratin 20 in peritoneal cells of cancer patients: are we aware of what we are detecting by mRNA examination?

Authors:  M Kowalewska; M Chechlinska; R Nowak
Journal:  Br J Cancer       Date:  2008-01-15       Impact factor: 7.640

10.  Evaluation of prognostic significance of circulating tumor cells detection in rectal cancer patients treated with preoperative radiotherapy: prospectively collected material data.

Authors:  Dominika Nesteruk; Andrzej Rutkowski; Stanisław Fabisiewicz; Jacek Pawlak; Janusz A Siedlecki; Anna Fabisiewicz
Journal:  Biomed Res Int       Date:  2014-05-21       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.